Researchers at UPMC and Penn State have developed a new mRNA vaccine platform that is more scalable and adaptable, offering rapid protection against viruses like COVID-19 and H5N1.
Roche’s Evrysdi® 5mg tablet for spinal muscular atrophy receives European Commission approval, offering a convenient, room-temperature stable treatment option for patients aged 2 and above.
Johnson & Johnson reports a 95% four-year progression-free survival rate using the DARZALEX FASPRO®-based regimen in transplant-eligible, newly diagnosed multiple myeloma patients who achieved sustained MRD negativity.
Amgen has revealed ground-breaking findings from its Phase 3 DeLLphi-304 clinical trial, showing that Imdelltra® (tarlatamab-dlle) dramatically decreased the risk of death in patients with extensive-stage small cell lung cancer (ES-SCLC) by 40% when compared to standard chemotherapy. Patients whose illness had worsened after receiving platinum-based chemotherapy were included in […]
The first stage of mitosis and meiosis, two crucial cellular division processes that support an organism’s growth, repair, and reproduction, is known as prophase.The specifics of what transpires and why differ depending on the cell’s activity in either mitosis or meiosis, even though chromosomal condensation and spindle construction are shared […]
Roche’s Itovebi™ (inavolisib) significantly improved overall survival in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer patients, according to final Phase III INAVO120 trial results.
Pfizer’s BRAFTOVI® combination regimen has demonstrated a 51% reduction in the risk of death and a 47% decrease in disease progression for patients with BRAF V600E-mutant metastatic colorectal cancer, according to the pivotal Phase 3 BREAKWATER trial.
Sanofi’s real-world study shows that infant immunization with BEYFORTUS® offers stronger protection against RSV-related hospitalizations compared to maternal immunization strategies.
Johnson & Johnson MedTech’s MONARCH™ Platform demonstrated 98.7% navigation success and 83.2% diagnostic yield in the TARGET study, confirming its safety and efficacy for robotically assisted bronchoscopy.
GSK has halted its Phase III PIVOT-PO trial early after an independent review confirmed tebipenem HBr met its primary efficacy goal in treating complicated urinary tract infections, marking a major step forward for oral antibiotic options.
